Abstract
Esophageal cancer is a lethal disease and the optimal therapy remains unclear. Neoadjuvant chemotherapy provides an increased chance of survival; therefore, we attempted to identify potential molecular markers that might improve evaluations of individual responses to therapy. We recruited 109 patients with resectable esophageal squamous cell carcinoma. The patients underwent radical esophagectomy and did not receive any other perioperative treatment. Expression of E2F-1 and molecules involved in its targeted pathways, pERK, Bim, pRb, epidermal growth factor receptor, EZH2 and pAKT, was investigated immunohistochemically. Correlations were observed between E2F-1 and pRb expression; EZH2 expression was significantly correlated with the degree of carcinoma differentiation (P = 0.01). Stage III patients were found to have longer survival if they did not express pERK than if they did (23 months vs. 11 months, P = 0.01). Patients with E2F-1 not expressing pRb were found to have longer survival times than those with E2F-1 who expressed pRb (18.8 months vs. 8.6 months, P = 0.021). Similarly, stage III patients with E2F-1 but not expressing pERK also survived longer than those expressing pERK (23.5 months vs. 3.9 months, P < 0.001). A h...Continue Reading
References
Nov 24, 1999·International Journal of Cancer. Journal International Du Cancer·A zur HausenH E Gabbert
Mar 1, 2000·Journal of Surgical Oncology·M IkeguchiN Kaibara
Oct 4, 2000·The Annals of Thoracic Surgery·M IkeguchiN Kaibara
Feb 24, 2001·Nature·M S SoengasS W Lowe
Sep 26, 2001·Journal of Cancer Research and Clinical Oncology·M IkeguchiN Kaibara
Dec 6, 2003·The New England Journal of Medicine·Peter C Enzinger, Robert J Mayer
Jul 3, 2004·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Y EbiharaH Katoh
Dec 3, 2004·Molecular Cell·Marie Chaussepied, Doron Ginsberg
Aug 2, 2005·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·S MegaS Kondo
Aug 30, 2005·Journal of Clinical Pathology·K YamazakiY Ishida
Mar 3, 2007·The Lancet Oncology·Val GebskiUNKNOWN Australasian Gastro-Intestinal Trials Group
Nov 12, 2009·International Journal of Cancer. Journal International Du Cancer·Li-Ru HeDan Xie
Feb 16, 2010·Nature Medicine·Junxia MinKaren Cichowski
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ju-Seog LeeIn-Sun Chu
Oct 22, 2010·Science Translational Medicine·Jesper B AndersenSnorri S Thorgeirsson
Nov 3, 2010·Annals of Surgery·D VallböhmerW Hofstetter
Dec 18, 2010·International Journal of Oncology·Atsushi YamadaAtsushi Ochiai
Mar 29, 2011·Oncogene·M Bug, M Dobbelstein
Feb 3, 2012·Cancer Research·David Engelmann, Brigitte M Pützer
Jul 7, 2012·Pathology, Research and Practice·Sang Yun Ha, Seok-Hyung Kim